UY36750A - Compuesto heterocíclico - Google Patents

Compuesto heterocíclico

Info

Publication number
UY36750A
UY36750A UY0001036750A UY36750A UY36750A UY 36750 A UY36750 A UY 36750A UY 0001036750 A UY0001036750 A UY 0001036750A UY 36750 A UY36750 A UY 36750A UY 36750 A UY36750 A UY 36750A
Authority
UY
Uruguay
Prior art keywords
present
disease
heterocyclic compound
compound
dementia
Prior art date
Application number
UY0001036750A
Other languages
English (en)
Inventor
Kimura Eiji
Kojima Takuto
Yamada Masami
Sugimoto Takahiro
Nakamura Minoru
Sakamoto Hiroki
Suzuki Shinkichi
Shimokawa Kenichiro
Ogino Masaki
Yonemori Jinichi
Murakami Masataka
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of UY36750A publication Critical patent/UY36750A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/20—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 4
    • C07D265/22—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C07F7/0814—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring is substituted at a C ring atom by Si
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La presente invención proporciona un compuesto con una actividad moduladora alostérica positiva del receptor muscarínico colinérgico M1, que puede ser útil como un fármaco preventivo o terapéutico para enfermedad de Alzheimer, esquizofrenia, dolor, trastorno del sueño, demencia por enfermedad de Parkinson, demencia por cuerpos de Lewy, y similares. La presente invención se refiere a un compuesto representado por la fórmula (I) o una de sus sales :en donde cada símbolo es como se define en la descripción adjunta.
UY0001036750A 2015-06-26 2016-06-23 Compuesto heterocíclico UY36750A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015129043 2015-06-26
JP2015206797 2015-10-20

Publications (1)

Publication Number Publication Date
UY36750A true UY36750A (es) 2017-01-31

Family

ID=56799518

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036750A UY36750A (es) 2015-06-26 2016-06-23 Compuesto heterocíclico

Country Status (23)

Country Link
US (5) US9878989B2 (es)
EP (1) EP3313836B1 (es)
JP (1) JP6745824B2 (es)
KR (1) KR20180019234A (es)
CN (1) CN107922403A (es)
AU (1) AU2016284654B9 (es)
CA (1) CA2988572A1 (es)
CL (1) CL2017003127A1 (es)
CO (1) CO2017012859A2 (es)
CR (1) CR20170568A (es)
DO (1) DOP2017000309A (es)
EA (1) EA201890152A1 (es)
HK (1) HK1248698A1 (es)
IL (1) IL256059A (es)
MX (1) MX2017016875A (es)
PE (1) PE20180500A1 (es)
PH (1) PH12017502351A1 (es)
TN (1) TN2017000508A1 (es)
TW (1) TW201710255A (es)
UA (1) UA121503C2 (es)
UY (1) UY36750A (es)
WO (1) WO2016208775A1 (es)
ZA (1) ZA201708387B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016206101A1 (en) 2015-06-26 2016-12-29 Merck Sharp & Dohme Corp. Metallo-beta-lactamase inhibitors
PE20180500A1 (es) * 2015-06-26 2018-03-09 Takeda Pharmaceuticals Co Derivados de 2,3-dihidro-4h-1,3-benzoxazin-4-ona como moduladores del receptor muscarinico colinergico m1
EP3366679B1 (en) 2015-10-20 2021-03-24 Takeda Pharmaceutical Company Limited Heterocyclic compound
EP3428150B1 (en) 2016-03-11 2023-07-12 Takeda Pharmaceutical Company Limited Aromatic ring compound having a cholinergic muscarine m1 receptor positive allosteric modulator activity
CN118005619A (zh) * 2017-02-28 2024-05-10 武田药品工业株式会社 用于生产杂环化合物的方法
WO2018194181A1 (en) 2017-04-18 2018-10-25 Takeda Pharmaceutical Company Limited Heterocyclic compounds useful as modulators of acetylcholine receptors
WO2018212312A1 (ja) 2017-05-19 2018-11-22 武田薬品工業株式会社 スクリーニング方法
BR112019026096A2 (pt) 2017-06-20 2020-07-07 Takeda Pharmaceutical Company Limited composto, medicamento, métodos para modulação alostérica positiva do receptor muscarínico colinérgico m1 e para a profilaxia ou o tratamento de constipação, e, uso do composto
FI3643718T3 (fi) 2017-06-20 2023-11-01 Takeda Pharmaceuticals Co Heterosyklinen yhdiste ja sen käyttö kolinergisen muskariini-m1-reseptorin positiivisena allosteerisena modulaattorina
JP7416537B2 (ja) * 2018-09-28 2024-01-17 武田薬品工業株式会社 複素環化合物
JP7446232B2 (ja) 2018-09-28 2024-03-08 武田薬品工業株式会社 縮合環化合物
WO2020067456A1 (ja) 2018-09-28 2020-04-02 武田薬品工業株式会社 複素環化合物
KR102288434B1 (ko) * 2018-10-18 2021-08-12 에이치케이이노엔 주식회사 신규한 (이소프로필-트리아졸릴)피리디닐 치환된 벤조옥사지논 또는 벤조티아지논 유도체 및 이의 용도
EP3870173A4 (en) 2018-10-24 2022-06-22 Vanderbilt University WDR5 MODULATORS AND INHIBITORS
WO2020247679A1 (en) * 2019-06-04 2020-12-10 Vanderbilt University Wdr5 inhibitors and modulators
CN114539035B (zh) * 2021-03-10 2023-08-18 山东新时代药业有限公司 一种七氟烷的合成方法

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5538983A (en) 1990-05-16 1996-07-23 The Rockefeller University Method of treating amyloidosis by modulation of calcium
CA2113115A1 (en) 1991-07-29 1993-02-18 Vlad E. Gregor Quinazoline derivatives as acetylcholinesterase inhibitors
IT1255179B (it) 1992-06-26 1995-10-20 Enzo Cereda Azaciclo e azabiciclo alchiliden idrossilamine
US5744476A (en) 1994-06-27 1998-04-28 Interneuron Pharmaceuticals, Inc. Dopamine D1 agonists for the treatment of dementia
JP2992677B2 (ja) 1995-06-05 1999-12-20 武田薬品工業株式会社 骨形成促進医薬組成物
WO1998030243A1 (en) 1997-01-08 1998-07-16 Warner-Lambert Company Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease
AU2231199A (en) 1998-01-16 1999-08-02 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Alkenyldiarylmethane non-nucleoside hiv-1 reverse transcriptase inhibitors
ATE346050T1 (de) 1998-01-27 2006-12-15 Aventis Pharma Inc Substituierte oxoazaheterocyclyl faktor xa hemmer
WO2000032590A1 (en) 1998-11-25 2000-06-08 Aventis Pharmaceuticals Products Inc. SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS
MXPA02000888A (es) 1999-07-28 2002-07-30 Aventis Pharm Prod Inc Compuestos de oxoazaheterociclilos substituidos.
JP2001131173A (ja) 1999-08-23 2001-05-15 Kyorin Pharmaceut Co Ltd 二環式複素環誘導体
JP2005231995A (ja) 1999-12-22 2005-09-02 Meiji Seika Kaisha Ltd オピオイドδ受容体アゴニスト／アンタゴニストとして有用なスピロ化合物
US7084126B1 (en) 2000-05-01 2006-08-01 Healthpartners Research Foundation Methods and compositions for enhancing cellular function through protection of tissue components
AU2001268055A1 (en) 2000-06-30 2002-01-14 Eli Lilly And Company Combination for treating psychoses, comprising an antipsychotic and a muscarinic agonist
JP2004532200A (ja) 2001-03-15 2004-10-21 サエジス ファーマシューティカルズ， インコーポレイテッド 全身性ストレスの後に認識機能を回復するための方法
US20040023951A1 (en) 2001-06-18 2004-02-05 Bymaster Franklin Porter Combination therapy for treatment of psychoses
US20030004913A1 (en) 2001-07-02 2003-01-02 Koninklijke Philips Electronics N.V. Vision-based method and apparatus for detecting an event requiring assistance or documentation
SK2292004A3 (en) 2001-11-26 2004-09-08 Cortex Pharma Inc Carbonyl benzoxazine compounds for enhancement of glutamatergic synaptic responses
US20040044023A1 (en) 2002-08-30 2004-03-04 Marc Cantillon Compositions and methods for treating or preventing memory impairment
US20060233843A1 (en) 2003-02-19 2006-10-19 Conn P J Treatment of psychosis with a muscarinic m1 receptor ectopic activator
NZ542690A (en) 2003-03-28 2009-04-30 Acadia Pharm Inc Muscarinic M1 receptor agonists for pain management
US20040266659A1 (en) 2003-06-27 2004-12-30 Stephen LaBerge Substances that enhance recall and lucidity during dreaming
GB0504019D0 (en) 2005-02-26 2005-04-06 Astrazeneca Ab Amide derivatives
WO2006113485A2 (en) 2005-04-15 2006-10-26 Board Of Trustees Of Michigan State University Aminergic pharmaceutical compositions and methods
GB0516570D0 (en) 2005-08-12 2005-09-21 Astrazeneca Ab Amide derivatives
US20110319386A1 (en) 2005-08-26 2011-12-29 Braincells Inc. Neurogenesis by muscarinic receptor modulation
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
WO2007044937A2 (en) 2005-10-13 2007-04-19 President And Fellows Of Harvard College Compositions and methods to modulate memory
ME02736B (me) 2005-12-21 2017-10-20 Janssen Pharmaceutica Nv Triazolopiridazini kao modulatori tirozin kinaze
GB0607952D0 (en) 2006-04-21 2006-05-31 Minster Res Ltd Novel treatment
GB0607949D0 (en) 2006-04-21 2006-05-31 Minster Res The Ltd Mono and combination therapy
GB0607946D0 (en) 2006-04-21 2006-05-31 Minster Res The Ltd Mono and combination therapy
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20121506A1 (es) 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
US8198448B2 (en) 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
US7834023B2 (en) 2006-09-20 2010-11-16 Portola Pharmaceuticals, Inc. Substituted dihydroquinazolines as platelet ADP receptor inhibitors
ME00819B (me) 2007-01-03 2012-03-20 Servier Lab 3-supstituisan-[1,2,3]-benzotriazinon jedinjenje za pojačavanje glutamatergičnih sinaptičkih odgovora
WO2008113072A2 (en) 2007-03-15 2008-09-18 Board Of Regents, The University Of Texas System Gpcr enhanced neuroprotection to treat brain injury
AR068106A1 (es) 2007-08-29 2009-11-04 Schering Corp Derivados de indol 2-carboxi sustituidos y una composicion farmaceutica
MX2010002318A (es) 2007-08-29 2010-03-22 Schering Corp Derivados azaindol 2,3-sustituidos para tratar infecciones virales.
EP2197842B1 (en) 2007-08-29 2012-05-23 Schering Corporation 2, 3-substituted indole derivatives for treating viral infections
US20090082342A1 (en) 2007-09-21 2009-03-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
SI2200610T1 (en) 2007-09-21 2018-06-29 Acadia Pharmaceuticals Inc. Co-administration of pimavanserin with other agents
JP5249344B2 (ja) 2007-11-16 2013-07-31 メルク・シャープ・アンド・ドーム・コーポレーション ヘテロ環の３位が置換されたインドール誘導体およびその使用
EP2222672B1 (en) 2007-11-16 2013-12-18 Merck Sharp & Dohme Corp. 3-aminosulfonyl substituted indole derivatives and methods of use thereof
US20110024198A1 (en) 2008-02-19 2011-02-03 Baker Hughes Incorporated Bearing systems containing diamond enhanced materials and downhole applications for same
WO2010042603A1 (en) 2008-10-08 2010-04-15 Cingulate Neuro Therapeutics, Llc Amyloid and depression
PT2358686E (pt) * 2008-11-20 2012-12-06 Merck Sharp & Dohme Moduladores alostéricos positivos do recetor m1 de aril metil benzoquinazolinona
AU2010216263A1 (en) 2009-02-23 2011-07-14 Merck Sharp & Dohme Corp. Pyrazolo [4,3-c] cinnolin-3-one M1 receptor positive allosteric modulators
SG174220A1 (en) 2009-03-05 2011-10-28 Mithridion Inc Compounds and compositions for cognition-enhancement, methods of making, and methods of treating
US8293744B2 (en) 2009-04-20 2012-10-23 Merck Sharp & Dohme Corp. Heterocyclic fused cinnoline M1 receptor positive allosteric modulators
ES2353093B1 (es) 2009-05-20 2012-01-03 Consejo Superior De Investigaciones Científicas (Csic) Uso de derivados de quinazolinas y sus composiciones farmacéuticas en enfermedades neurodegenerativas.
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
ES2742728T3 (es) 2009-07-22 2020-02-17 PureTech Health LLC Composiciones para el tratamiento de trastornos mejorados por la activación del receptor muscarínico
ES2537979T3 (es) * 2009-08-31 2015-06-16 Merck Sharp & Dohme Corp. Moduladores alostéricos positivos del receptor M1 de piranilarilmetilbenzoquinazolinona
EP2490692B1 (en) 2009-10-21 2016-11-16 Merck Sharp & Dohme Corp. Quinolinone-pyrazolone m1 receptor positive allosteric modulators
WO2011075371A1 (en) 2009-12-14 2011-06-23 Merck Sharp & Dohme Corp. Pyridoquinazolinone m1 receptor positive allosteric modulators
US8383638B2 (en) * 2009-12-21 2013-02-26 Merck Sharp & Dohme Aminobenzoquinazolinone M1 receptor positive allosteric modulators
EP2582241B1 (en) 2010-06-15 2016-04-06 Merck Sharp & Dohme Corp. Heterocyclic fused phenanthrolinone m1 receptor positive allosteric modulators
US8697690B2 (en) 2010-07-01 2014-04-15 Merck Sharp & Dohme Corp. Isoindolone M1 receptor positive allosteric modulators
EP2624697B1 (en) 2010-10-04 2015-11-25 Merck Sharp & Dohme Corp. Dihydrobenzoquinazolinone m1 receptor positive allosteric modulators
US9549928B2 (en) 2011-04-29 2017-01-24 The University Of Toledo Muscarinic agonists as enhancers of cognitive flexibility
EP2709624B1 (en) * 2011-05-17 2016-04-27 Merck Sharp & Dohme Corp. N-methyl tetrahydroquinoline m1 receptor positive allosteric modulators
WO2012170599A1 (en) 2011-06-10 2012-12-13 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
US9403802B2 (en) 2012-03-02 2016-08-02 Takeda Pharmaceutical Company Limited Heterocyclic compound and use therefor
EP2828247B1 (en) 2012-03-23 2019-01-16 PTC Therapeutics, Inc. 4h-chromen-4-one derivatives for treating spinal muscular atrophy
US20130289019A1 (en) 2012-04-26 2013-10-31 Amazing Grace, Inc. Methods of treating behaviorial and/or mental disorders
WO2014077401A1 (ja) 2012-11-19 2014-05-22 武田薬品工業株式会社 含窒素複素環化合物
JP6075408B2 (ja) 2012-11-22 2017-02-08 株式会社デンソー 物標検出装置
CN104903300B (zh) 2012-12-27 2018-04-17 霍夫曼-拉罗奇有限公司 Comt抑制剂
AU2014211728B2 (en) 2013-02-04 2018-05-17 Merck Patent Gmbh Spiro-quinazolinone derivatives useful for the treatment of neurological diseases and conditions
EP2994460A4 (en) 2013-05-06 2017-02-08 Indiana University Research and Technology Corporation Compounds for treatment of angiogenesis-mediated diseases
JP6063400B2 (ja) 2014-01-08 2017-01-18 株式会社日立ビルシステム エレベータの異常監視装置
MY195742A (en) 2014-04-23 2023-02-08 Takeda Pharmaceuticals Co Isoindoline-1-One Derivatives as Cholinergic Muscarinic M1 Receptor Positive Alloesteric Modulator Activity for the Treatment of Alzheimers Disease
JP6531093B2 (ja) 2014-05-16 2019-06-12 武田薬品工業株式会社 含窒素複素環化合物
JP6571077B2 (ja) 2014-06-13 2019-09-04 武田薬品工業株式会社 含窒素複素環化合物
PE20180500A1 (es) * 2015-06-26 2018-03-09 Takeda Pharmaceuticals Co Derivados de 2,3-dihidro-4h-1,3-benzoxazin-4-ona como moduladores del receptor muscarinico colinergico m1
US20180250270A1 (en) 2015-09-11 2018-09-06 Chase Pharmaceuticals Corporation Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system
EP3366679B1 (en) 2015-10-20 2021-03-24 Takeda Pharmaceutical Company Limited Heterocyclic compound
EP3428150B1 (en) 2016-03-11 2023-07-12 Takeda Pharmaceutical Company Limited Aromatic ring compound having a cholinergic muscarine m1 receptor positive allosteric modulator activity
US20200188388A1 (en) 2016-12-29 2020-06-18 Rvx Therapeutics Ltd. Methods and compositions for potentiating cns drugs and reducing their side effects

Also Published As

Publication number Publication date
US20180050996A1 (en) 2018-02-22
TW201710255A (zh) 2017-03-16
CA2988572A1 (en) 2016-12-29
CL2017003127A1 (es) 2018-06-08
IL256059A (en) 2018-01-31
EA201890152A1 (ru) 2018-08-31
AU2016284654A1 (en) 2018-01-04
KR20180019234A (ko) 2018-02-23
PH12017502351A1 (en) 2018-06-25
JP2018524338A (ja) 2018-08-30
US10899752B2 (en) 2021-01-26
JP6745824B2 (ja) 2020-08-26
US10428056B2 (en) 2019-10-01
TN2017000508A1 (en) 2019-04-12
US9878989B2 (en) 2018-01-30
US20180162850A1 (en) 2018-06-14
CR20170568A (es) 2018-04-20
US20190248776A1 (en) 2019-08-15
WO2016208775A1 (en) 2016-12-29
US10087150B2 (en) 2018-10-02
HK1248698A1 (zh) 2018-10-19
CN107922403A (zh) 2018-04-17
AU2016284654B9 (en) 2020-05-21
US10323027B2 (en) 2019-06-18
UA121503C2 (uk) 2020-06-10
EP3313836A1 (en) 2018-05-02
ZA201708387B (en) 2019-05-29
CO2017012859A2 (es) 2018-03-28
MX2017016875A (es) 2018-04-24
EP3313836B1 (en) 2020-11-11
US20160376244A1 (en) 2016-12-29
DOP2017000309A (es) 2018-04-30
US20180362516A1 (en) 2018-12-20
AU2016284654B2 (en) 2020-01-23
PE20180500A1 (es) 2018-03-09

Similar Documents

Publication Publication Date Title
DOP2017000309A (es) Derivados de 2,3-dihidro-4h-1,3-benzoxazin-4-ona como moduladores de receptor muscarinico m1 cholinergico
ECSP16090152A (es) Compuesto heterocíclico que contiene nitrógeno
UY35377A (es) Compuestos de 1,3-oxazin-2-amina fusionados con ciclopropilo perfluorado como inhibidores de beta-secretasa y métodos de uso
ECSP13012478A (es) Compuesto heterocíclico y su uso
CO2018009889A2 (es) Moduladores alostéricos de receptores de acetilcolina nicotínicos
GT201400301A (es) 7h-pirrolo [2,3-d] pirimidinas-4- ( aminho-substituidas) novedosas como inhibidores de lrrk2
UY35361A (es) COMPUESTOS PERFLUORADOS DE 5,6-DIHIDRO-4H-1,3-OXAZIN-2-AMINA COMO INHIBIDORES DE BETA-SECRETASA y MÉTODOS DE USO
AR095823A1 (es) Compuesto de ciclopropanamina y uso del mismo
ECSP17035415A (es) 2-Amino-5,5-difluoro-6-(fluorometil)-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de BACE1
UY36263A (es) Compuestos de tiazin-2-amina fusionados con ciclopropilo como inhibidores de beta-secretasa y métodos de uso
UY36218A (es) “derivados de piridina como moduladores alostéricos positivos del receptor muscarínico m1”
UY37311A (es) Derivados de 5,7-dihidro-pirrolo-piridina
SV2017005354A (es) Derivados de quinolizinona como inhibidores de pi3k
BR112015022907A8 (pt) formas cristalinas de sal de (2-(2-(4-fluorfenil) tiazol-4-il) propan-2-il) carbamato de (s)-quinuclidin-3-ila e seus usos
BR112018003489A2 (pt) n-[2-(2-amino-6,6-dissubstituído-4,4a,5,6-tetra-hidropirano[3,4-d][1,3]tiazin-8a(8h)-il)-1,3-tiazol-4-il]amidas
CR20150646A (es) 4-(5-(4-clorofenil)-2-(2-ciclopropilacetil)-1,4-dimetil-1h-pirrol-3-il)bencenosulfonamida como modulador de nachr alfa
CO2017004785A2 (es) N-[4-(2-furil)-5-(tetrahidropiran-4-ilcarbonil)tiazol-2-il]-2-metilpiridin-5-carboxamida o una sal farmacéutica como antagonista del receptor a2a
UY35685A (es) Compuestos de dióxido de amino tiazina bicíclicos puenteados como inhibidores de beta-secretasa y sus métodos de uso
ECSP18006622A (es) Derivados de 2,3-dihidro-4h-1,3-benzoxazin-4-ona como moduladores de receptor muscarinico m1 cholinergico
SV2017005527A (es) Agente terapéutico para disfunción del lóbulo frontal
AR105869A1 (es) Regímenes para tratar y prevenir trastornos lisosomales y trastornos degenerativos del sistema nervioso central
CU20140140A7 (es) 7H-PIRROLO[2,3-d]PIRIMIDINAS 4-(AMINO-SUBSTITUIDAS) NOVEDOSAS COMO INHIBIDORES DE LRRK2

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20221129